Borchard, Gerrit

Link to this page

Authority KeyName Variants
1c0ad992-f391-4b5f-b3f7-813ac3851ca8
  • Borchard, Gerrit (5)

Author's Bibliography

The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73

Đoković, Jelena; Nikolić, Ines; Sharmin, Dishary; Cook, James M.; Savić, Miroslav; Borchard, Gerrit; Savić, Snežana

(International Society of Drug Delivery Sciences and Technology (APGI), 2024)

TY  - CONF
AU  - Đoković, Jelena
AU  - Nikolić, Ines
AU  - Sharmin, Dishary
AU  - Cook, James M.
AU  - Savić, Miroslav
AU  - Borchard, Gerrit
AU  - Savić, Snežana
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5575
AB  - INTRODUCTION Temporal lobe epilepsy is characterized by seizures, but can also be associated with mental health problems for which there are no clear treatment regimens. A proprietary compound, GL-II-73 - (4R)-8-ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide, a positive allosteric modulator of α5-containing γ-aminobutyric acid (GABA) receptors, has been shown to be effective in the treatment of these comorbidities [1]. ...
PB  - International Society of Drug Delivery Sciences and Technology (APGI)
PB  - International Association for Pharmaceutical Technology (APV)
PB  - Italian Society of Technology and Legislation (S.T.E.L.F)
C3  - 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria
T1  - The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5575
ER  - 
@conference{
author = "Đoković, Jelena and Nikolić, Ines and Sharmin, Dishary and Cook, James M. and Savić, Miroslav and Borchard, Gerrit and Savić, Snežana",
year = "2024",
abstract = "INTRODUCTION Temporal lobe epilepsy is characterized by seizures, but can also be associated with mental health problems for which there are no clear treatment regimens. A proprietary compound, GL-II-73 - (4R)-8-ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide, a positive allosteric modulator of α5-containing γ-aminobutyric acid (GABA) receptors, has been shown to be effective in the treatment of these comorbidities [1]. ...",
publisher = "International Society of Drug Delivery Sciences and Technology (APGI), International Association for Pharmaceutical Technology (APV), Italian Society of Technology and Legislation (S.T.E.L.F)",
journal = "14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria",
title = "The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5575"
}
Đoković, J., Nikolić, I., Sharmin, D., Cook, J. M., Savić, M., Borchard, G.,& Savić, S.. (2024). The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73. in 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria
International Society of Drug Delivery Sciences and Technology (APGI)..
https://hdl.handle.net/21.15107/rcub_farfar_5575
Đoković J, Nikolić I, Sharmin D, Cook JM, Savić M, Borchard G, Savić S. The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73. in 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria. 2024;.
https://hdl.handle.net/21.15107/rcub_farfar_5575 .
Đoković, Jelena, Nikolić, Ines, Sharmin, Dishary, Cook, James M., Savić, Miroslav, Borchard, Gerrit, Savić, Snežana, "The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73" in 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria (2024),
https://hdl.handle.net/21.15107/rcub_farfar_5575 .

Sizing up the nanomedicines: a thorough examination of techniques and data interpretation

Nikolić, Ines; Đoković, Jelena; Mehn, Dora; Guerrini, Giuditta; Colpo, Pascal; Jordan, Olivier; Savić, Snežana; Borchard, Gerrit

(French Society for Nanomedicine (SFNano), 2023)

TY  - CONF
AU  - Nikolić, Ines
AU  - Đoković, Jelena
AU  - Mehn, Dora
AU  - Guerrini, Giuditta
AU  - Colpo, Pascal
AU  - Jordan, Olivier
AU  - Savić, Snežana
AU  - Borchard, Gerrit
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5427
AB  - Size is a universal and first in mind property relevant for nanomedicine/nanomaterial
characterization, representing the most suitable measurand. However, due to the acknowledged
lack of standardized protocols that are able to provide reliable results, especially in the
biorelevant context, researchers often engage with the procedures that are successful in
acquiring data, but not necessarily the correct ones. ...
PB  - French Society for Nanomedicine (SFNano)
C3  - 9th SFNano annual meeting; December 4th - 6th, Montpellier, France
T1  - Sizing up the nanomedicines: a thorough examination of techniques and data interpretation
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5427
ER  - 
@conference{
author = "Nikolić, Ines and Đoković, Jelena and Mehn, Dora and Guerrini, Giuditta and Colpo, Pascal and Jordan, Olivier and Savić, Snežana and Borchard, Gerrit",
year = "2023",
abstract = "Size is a universal and first in mind property relevant for nanomedicine/nanomaterial
characterization, representing the most suitable measurand. However, due to the acknowledged
lack of standardized protocols that are able to provide reliable results, especially in the
biorelevant context, researchers often engage with the procedures that are successful in
acquiring data, but not necessarily the correct ones. ...",
publisher = "French Society for Nanomedicine (SFNano)",
journal = "9th SFNano annual meeting; December 4th - 6th, Montpellier, France",
title = "Sizing up the nanomedicines: a thorough examination of techniques and data interpretation",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5427"
}
Nikolić, I., Đoković, J., Mehn, D., Guerrini, G., Colpo, P., Jordan, O., Savić, S.,& Borchard, G.. (2023). Sizing up the nanomedicines: a thorough examination of techniques and data interpretation. in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France
French Society for Nanomedicine (SFNano)..
https://hdl.handle.net/21.15107/rcub_farfar_5427
Nikolić I, Đoković J, Mehn D, Guerrini G, Colpo P, Jordan O, Savić S, Borchard G. Sizing up the nanomedicines: a thorough examination of techniques and data interpretation. in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_5427 .
Nikolić, Ines, Đoković, Jelena, Mehn, Dora, Guerrini, Giuditta, Colpo, Pascal, Jordan, Olivier, Savić, Snežana, Borchard, Gerrit, "Sizing up the nanomedicines: a thorough examination of techniques and data interpretation" in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France (2023),
https://hdl.handle.net/21.15107/rcub_farfar_5427 .

The Landscape of Nanomedicines: An Expert Perspective

Nikolić, Ines; Filipić, Brankica; Marija Petrović; Jordan, Olivier; Savić, Snežana; Borchard, Gerrit

(Savez farmaceutskih udruženja Srbije, 2023)

TY  - JOUR
AU  - Nikolić, Ines
AU  - Filipić, Brankica
AU  - Marija Petrović
AU  - Jordan, Olivier
AU  - Savić, Snežana
AU  - Borchard, Gerrit
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5358
AB  - The field of nanotechnology is at the forefront of a scientific revolution, where the term
“nano” transcends mere size and opens the door to enormous possibilities.
In the context of drug development, the selection of a suitable drug delivery system
(corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly,
nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining
recognition for addressing healthcare issues.
While these products hold immense promise, they have faced certain complexities in their
translation from the preclinical to the clinical setting, reflected in the lack of proper assessment
protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory
environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of
liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory
approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in
the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their
significance. However, the relatively modest number of approved nanomedicines compared to the
extensive research efforts raises important questions and underscores areas of uncertainty.
This article provides an overview of the challenges in defining nanomedicines, their
properties, the complexities of regulatory frameworks, and the imperative for standardized
characterization protocols.
AB  - Polje nanotehnologije se nalazi na čelu naučne revolucije, gde se termin "nano" izdiže iznad pukog označavanja veličine, otvarajući vrata novim mogućnostima. U kontekstu razvoja lekova, izbor odgovarajućeg sistema za isporuku / nosača (koji odgovara određenoj aktivnoj supstanci) predstavlja ključnu odluku. U tom kontekstu, nanosistemi već određeno vreme predstavljaju inovativna rešenja. Iako farmaceutski nanosistemi nose ogroman potencijal, suočavaju se sa određenim izazovima u pogledu translacije sa prekliničkog na klinički nivo, što se ogleda u nedostatku odgovarajućih protokola za ispitivanje kvaliteta i bezbednosti i, shodno tome, nedefinisanom regulatornom okruženju. Od revolucionarnog odobrenja liposomalnog doksorubicina od strane Američke agencije za hranu i lekove 1995. godine, pa sve do danas, oko 80 nano formulacija (nanolekova) odobreno je za kliničku primenu. Odnedavno je intenzivnija pažnja usmerena ka nanoformulacijama baziranim na lipidima, što je delom posledica razvoja mRNK vakcina tokom pandemije COVID-19. Međutim, relativno skroman nastup nanolekova na tržištu (u poređenju sa obimnim istraživačkim naporima i finansijskim ulaganjima u ovu oblast) otvara važna pitanja. Ovaj rad pruža pregled izazova u definisanju nanolekova, njihovih svojstava, kompleksnosti regulatornih okvira i imperativa za stvaranje standardizovanih protokola karakterizacije.
PB  - Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - The Landscape of Nanomedicines: An Expert Perspective
T1  - "Pejzažni" prikaz nanolekova - ekspertska perspektiva
VL  - 73
IS  - 5
SP  - 390
EP  - 403
DO  - 10.5937/arhfarm73-46686
ER  - 
@article{
author = "Nikolić, Ines and Filipić, Brankica and Marija Petrović and Jordan, Olivier and Savić, Snežana and Borchard, Gerrit",
year = "2023",
abstract = "The field of nanotechnology is at the forefront of a scientific revolution, where the term
“nano” transcends mere size and opens the door to enormous possibilities.
In the context of drug development, the selection of a suitable drug delivery system
(corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly,
nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining
recognition for addressing healthcare issues.
While these products hold immense promise, they have faced certain complexities in their
translation from the preclinical to the clinical setting, reflected in the lack of proper assessment
protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory
environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of
liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory
approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in
the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their
significance. However, the relatively modest number of approved nanomedicines compared to the
extensive research efforts raises important questions and underscores areas of uncertainty.
This article provides an overview of the challenges in defining nanomedicines, their
properties, the complexities of regulatory frameworks, and the imperative for standardized
characterization protocols., Polje nanotehnologije se nalazi na čelu naučne revolucije, gde se termin "nano" izdiže iznad pukog označavanja veličine, otvarajući vrata novim mogućnostima. U kontekstu razvoja lekova, izbor odgovarajućeg sistema za isporuku / nosača (koji odgovara određenoj aktivnoj supstanci) predstavlja ključnu odluku. U tom kontekstu, nanosistemi već određeno vreme predstavljaju inovativna rešenja. Iako farmaceutski nanosistemi nose ogroman potencijal, suočavaju se sa određenim izazovima u pogledu translacije sa prekliničkog na klinički nivo, što se ogleda u nedostatku odgovarajućih protokola za ispitivanje kvaliteta i bezbednosti i, shodno tome, nedefinisanom regulatornom okruženju. Od revolucionarnog odobrenja liposomalnog doksorubicina od strane Američke agencije za hranu i lekove 1995. godine, pa sve do danas, oko 80 nano formulacija (nanolekova) odobreno je za kliničku primenu. Odnedavno je intenzivnija pažnja usmerena ka nanoformulacijama baziranim na lipidima, što je delom posledica razvoja mRNK vakcina tokom pandemije COVID-19. Međutim, relativno skroman nastup nanolekova na tržištu (u poređenju sa obimnim istraživačkim naporima i finansijskim ulaganjima u ovu oblast) otvara važna pitanja. Ovaj rad pruža pregled izazova u definisanju nanolekova, njihovih svojstava, kompleksnosti regulatornih okvira i imperativa za stvaranje standardizovanih protokola karakterizacije.",
publisher = "Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "The Landscape of Nanomedicines: An Expert Perspective, "Pejzažni" prikaz nanolekova - ekspertska perspektiva",
volume = "73",
number = "5",
pages = "390-403",
doi = "10.5937/arhfarm73-46686"
}
Nikolić, I., Filipić, B., Marija Petrović, Jordan, O., Savić, S.,& Borchard, G.. (2023). The Landscape of Nanomedicines: An Expert Perspective. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije., 73(5), 390-403.
https://doi.org/10.5937/arhfarm73-46686
Nikolić I, Filipić B, Marija Petrović, Jordan O, Savić S, Borchard G. The Landscape of Nanomedicines: An Expert Perspective. in Arhiv za farmaciju. 2023;73(5):390-403.
doi:10.5937/arhfarm73-46686 .
Nikolić, Ines, Filipić, Brankica, Marija Petrović, Jordan, Olivier, Savić, Snežana, Borchard, Gerrit, "The Landscape of Nanomedicines: An Expert Perspective" in Arhiv za farmaciju, 73, no. 5 (2023):390-403,
https://doi.org/10.5937/arhfarm73-46686 . .

Navigating towards improved cytotoxicity assessment in nanomedicine development: Shifting from colorimetric to fluorescence-based assays

Nikolić, Ines; Petrović, Marija; Mitrović, Jelena; Sublet, Emmanuelle; Jordan, Oliver; Savić, Snežana; Borchard, Gerrit

(International Association of Physical Chemists, 2023)

TY  - CONF
AU  - Nikolić, Ines
AU  - Petrović, Marija
AU  - Mitrović, Jelena
AU  - Sublet, Emmanuelle
AU  - Jordan, Oliver
AU  - Savić, Snežana
AU  - Borchard, Gerrit
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5007
AB  - It is well known that the characterization of nanomedicines can pursue different levels of complexity, both in the development stage and in the quality control process [1]. In line with physicochemical aspects, even more obstacles are encountered in biological safety assessment, while anticipation of their immunogenic potential represents an additional challenge. Moreover, interactions between the test reagents and the nanomaterial have been identified as one of the most important issues in toxicity testing that influence market authorization of nanomedicines, which ought to be resolved [1]. The European Nanomedicine Characterization Laboratory – the reference laboratory for nanomedicines, provides protocols for 2 colorimetric cytotoxicity assays employing LLC-PK1 (porcine kidney epithelial cells) and Hep-G2 (human hepatocarcinoma cells) cell lines. However, the latest recommendations in the field underline the demand for enhancing the testing procedures, while proposing incorporation of immune cells as target cell lines for toxicity evaluation, aiming to provide more reliable conclusions on nanomedicine safety in preclinical level.
In this study 2 inherently different types of pharmaceutical nanosystemes were selected: nanoemulsion (NE) and solid lipid nanoparticles (LNP) and subjected to a set of orthogonal toxicity evaluation assays. Adjusted WST-1 (assessing mitochondrial activity as an indicator of cellular well-being) and LDH (lactate dehydrogenase release evaluation as an indicator of cell membrane damage) assays have been performed as the colorimetric tests, while propidium-iodide (PI)-based assay was developed as a fluore-scent counterpart (able to directly distinguish live from dead cells), using RAW 246.7 cell line (murine macrophages – immune system cell line). Starting concentration of the tested nanoformulations was 50 % v/v, and they were subsequently diluted with the factor of 2, to create a total of 8 concentrations. Incubation time was 4 h.
Presented assays rely on completely different biological bases. Therefore, their careful combination can address some shortcomings in the in vitro evaluations established so far. Although similar toxicity trends were observed regardless the assay used, it was evident that the LDH assay required specific consideration. Since the supernatant is the subject of the analysis (not the cells directly), containing not only the enzyme of interest, but also the nanoformulations, in the wells corresponding to the 3 highest concentration of the NE/LNP pronounced scattering effects were observed. Such an event could be easily overlooked, potentially affecting the conclusions. However, it was overcome by careful design of control and blank wells (each test concentration was coupled with its own blank well containing no cells, but the same concentration of the NE/LNP in the culture medium). In contrast, absorbance measurements in WST-1 assay were performed in the absence of the NE/LNP, avoiding any interactions or scattering effects. Finally, developed PI-based assay proved to be the most relevant method. Based on the penetration of PI into the dead cell only, attaching to their DNA, the concentration of the dead vs. live cells could be directly estimated. What is more, after the incubation time, the measurements can be performed in the nanoformulation-free environment, surpas-sing the potential interactions. Notably, cell viability obtained in the PI-based assay followed the same trend as in the WST-1 assay but with significant difference in the obtained values for the first 3 concentrations (Figure 1).
PB  - International Association of Physical Chemists
C3  - 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
T1  - Navigating towards improved cytotoxicity assessment in nanomedicine development: Shifting from colorimetric to fluorescence-based assays
SP  - 21
EP  - 21
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5007
ER  - 
@conference{
author = "Nikolić, Ines and Petrović, Marija and Mitrović, Jelena and Sublet, Emmanuelle and Jordan, Oliver and Savić, Snežana and Borchard, Gerrit",
year = "2023",
abstract = "It is well known that the characterization of nanomedicines can pursue different levels of complexity, both in the development stage and in the quality control process [1]. In line with physicochemical aspects, even more obstacles are encountered in biological safety assessment, while anticipation of their immunogenic potential represents an additional challenge. Moreover, interactions between the test reagents and the nanomaterial have been identified as one of the most important issues in toxicity testing that influence market authorization of nanomedicines, which ought to be resolved [1]. The European Nanomedicine Characterization Laboratory – the reference laboratory for nanomedicines, provides protocols for 2 colorimetric cytotoxicity assays employing LLC-PK1 (porcine kidney epithelial cells) and Hep-G2 (human hepatocarcinoma cells) cell lines. However, the latest recommendations in the field underline the demand for enhancing the testing procedures, while proposing incorporation of immune cells as target cell lines for toxicity evaluation, aiming to provide more reliable conclusions on nanomedicine safety in preclinical level.
In this study 2 inherently different types of pharmaceutical nanosystemes were selected: nanoemulsion (NE) and solid lipid nanoparticles (LNP) and subjected to a set of orthogonal toxicity evaluation assays. Adjusted WST-1 (assessing mitochondrial activity as an indicator of cellular well-being) and LDH (lactate dehydrogenase release evaluation as an indicator of cell membrane damage) assays have been performed as the colorimetric tests, while propidium-iodide (PI)-based assay was developed as a fluore-scent counterpart (able to directly distinguish live from dead cells), using RAW 246.7 cell line (murine macrophages – immune system cell line). Starting concentration of the tested nanoformulations was 50 % v/v, and they were subsequently diluted with the factor of 2, to create a total of 8 concentrations. Incubation time was 4 h.
Presented assays rely on completely different biological bases. Therefore, their careful combination can address some shortcomings in the in vitro evaluations established so far. Although similar toxicity trends were observed regardless the assay used, it was evident that the LDH assay required specific consideration. Since the supernatant is the subject of the analysis (not the cells directly), containing not only the enzyme of interest, but also the nanoformulations, in the wells corresponding to the 3 highest concentration of the NE/LNP pronounced scattering effects were observed. Such an event could be easily overlooked, potentially affecting the conclusions. However, it was overcome by careful design of control and blank wells (each test concentration was coupled with its own blank well containing no cells, but the same concentration of the NE/LNP in the culture medium). In contrast, absorbance measurements in WST-1 assay were performed in the absence of the NE/LNP, avoiding any interactions or scattering effects. Finally, developed PI-based assay proved to be the most relevant method. Based on the penetration of PI into the dead cell only, attaching to their DNA, the concentration of the dead vs. live cells could be directly estimated. What is more, after the incubation time, the measurements can be performed in the nanoformulation-free environment, surpas-sing the potential interactions. Notably, cell viability obtained in the PI-based assay followed the same trend as in the WST-1 assay but with significant difference in the obtained values for the first 3 concentrations (Figure 1).",
publisher = "International Association of Physical Chemists",
journal = "10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6",
title = "Navigating towards improved cytotoxicity assessment in nanomedicine development: Shifting from colorimetric to fluorescence-based assays",
pages = "21-21",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5007"
}
Nikolić, I., Petrović, M., Mitrović, J., Sublet, E., Jordan, O., Savić, S.,& Borchard, G.. (2023). Navigating towards improved cytotoxicity assessment in nanomedicine development: Shifting from colorimetric to fluorescence-based assays. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
International Association of Physical Chemists., 21-21.
https://hdl.handle.net/21.15107/rcub_farfar_5007
Nikolić I, Petrović M, Mitrović J, Sublet E, Jordan O, Savić S, Borchard G. Navigating towards improved cytotoxicity assessment in nanomedicine development: Shifting from colorimetric to fluorescence-based assays. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6. 2023;:21-21.
https://hdl.handle.net/21.15107/rcub_farfar_5007 .
Nikolić, Ines, Petrović, Marija, Mitrović, Jelena, Sublet, Emmanuelle, Jordan, Oliver, Savić, Snežana, Borchard, Gerrit, "Navigating towards improved cytotoxicity assessment in nanomedicine development: Shifting from colorimetric to fluorescence-based assays" in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6 (2023):21-21,
https://hdl.handle.net/21.15107/rcub_farfar_5007 .

Sizing experiments and bio-nano interactions: method matters

Nikolić, Ines; Petrović, Marija; Krupnik, Leondard; Ranđelović, Danijela; Avaro, Jonathan; Neels, Antonia; Borchard, Gerrit; Jordan, Olivier; Đoković, Jelena; Savić, Snežana

(2023)

TY  - CONF
AU  - Nikolić, Ines
AU  - Petrović, Marija
AU  - Krupnik, Leondard
AU  - Ranđelović, Danijela
AU  - Avaro, Jonathan
AU  - Neels, Antonia
AU  - Borchard, Gerrit
AU  - Jordan, Olivier
AU  - Đoković, Jelena
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4571
AB  - INTRODUCTION
Physicochemical properties of many active ingredients jeopardize their pharmacological activity. To overcome identified obstacles, nanosystems as carriers for delivery of actives have been recognized as promising tools. Increasing number of applications for registration of nanotechnology-enabled pharmaceuticals and many more currently in preclinical or clinical studies raised some questions not only in the field of research and development, but also for regulators. Given the complexity of nanosystems, some specific challenges have been encountered in their characterization, which have not been fully addressed despite respectable research tradition in this field.  Particle size and aggregation potential (especially in complex biological fluids) are some of the critical quality attributes of nanomedicines, being important in the context of physical stability of the colloidal system, and in terms of its safety profile and in vivo performance. Even though a bright future has been predicted for nanomedicines, some of the posted expectations have not been fully met so far. This might be reflected, at least at some points, in the certain methodological issues that commonly result in in vitro to in vivo translational gaps. This aspect underlines the importance of quality and safety assessment of nanomedicines which has also been recognized by globally leading research and regulatory bodies [1,2]. Therefore, the aim of the presented research was to perform a thorough analysis of the selected nanosystem (nanoemulsion) focusing on size estimation and particle-protein interaction applying several techniques, highlighting important factors for a reliable analysis.
METHODLOGY
Materials
As a model nanosystem, previously developed nanoemulsion was used, containing medium-chain triglycerides (Mygliol 812, Fagron) as the oil phase, combination of polysorbate 80 (Acros Organics) and soybean lecithin (Lipoid S-75, Lipoid) as stabilizes, and highly purified water as the water phase. For protein interaction assessment, human serum albumin was used (HSA, Sigma Aldrich).
Methods
Nanoemulsion preparation
Nanoemulsion was prepared via spontaneous emulsification, by dropwise addition of the mixture of the oil and stabilizers to the water phase under constant stirring. For nanoparticle-protein interaction assesment, nanoemulsion was incubated (1h, 37 °C) with HSA in the final concentration of 2.5 mg/ml. 
Sizing experiments – dynamic light scattering
Size and size distribution (per se and in biorelevant environment) were evaluated applying batch mode dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments, UK), following the NCL guidance [3]. Intensity-based average hydrodynamic diameter (Z-ave) and polydispersity index (PDI) were analysed in line with relevant parameters of the method. 
Atomic force microscopy (AFM)
Additional sizing analysis and morphological evaluation of the sample were performed applying AFM as a high-resolution technique. AFM analysis of the samples was performed by NTEGRA Prima atomic force microscope (NT-MDT, Moscow, Russia). Intermittent-contact AFM mode was applied using NT-MDT NSGO1 silicon, N-type, antimony doped cantilevers with Au reflective coating. Sample dilution corresponded to the optimal one selected for DLS, and 10 μl of the dilution was placed to the high-quality silica discs (Highest Grade V1 Mica Discs, Ted Pella Inc.) and dried in vacuum. Experiments were performed in the air, in contactless mode. Topographic images and “signal-error” images were collected, AFM images were created and analyzed with the software Image Analysis 2.2.0 (NT-MDT) and Gwyddion 2.60 (Free and Open Source software, Department of Nanometrology, Czech Metrology Institute).
Small angle X-ray scattering (SAXS)
SAXS experiments were performed with the general idea to analyze the structure of the dispersed nanodroplets more profoundly, and especially interactions in biorelevant surrounding (in contact with HSA). A laboratory X-ray setup was applied (Bruker Nanostar, Bruker AXS GmbH, Karlsruhe, Germany). Here, the Kα-line of a X-ray Cu source with a wavelength of 1.541 Å was used and further monochromated by a X-ray mirror. The beam was collimated to a beam diameter of approximately 0.4 mm using three pinholes. The sample-detector distance was set to 107 cm, which lead to a q-range of 0.07 ≤ q ≤ 2.3 nm-1. Calibration of the scattering vector q and estimation of the instrumental resolution of Δq = 0.25 nm-1 was done by measuring the first diffraction peak of a silver behenate sample. The scattered intensity was measured with an avalanche-based detector (VÅNTEC-2000, Bruker AXS). The transmitted part of the beam was determined using a home-made semi-transparent beam stop. The scattered intensity was extracted, radially averaged and integrated over all q-values using the Bruker software DIF-FRAC.EVA (Bruker AXS, version 4.1). The 1D data was transmission corrected and then background subtracted from the scattering of the solvent and the capillary using Matlab 2022.
RESULTS AND DISCUSSION
When applying DLS, as a preliminary technique, primary attention was put on the selection of optimal dilution level for the measurement, analyzing attenuation factor, count rate and intercept of the correlation function in different dilution ratios and with different dilution media (water, PBS 7.4 and 10 mM NaCl), and dilution 1:100 (v/v) was marked as the optimal one. However, significant differences in obtained nanodroplet size was observed depending on the type of medium. When water was used as a dilution medium, significantly higher Z-ave values were obtained (83.71±0.86 nm) compared to the situations where PBS 7.4 (73.50±0.75nm) or 10 mM NaCl (76.59±0.50nm) were used as dilution medium, indicating how sample preparation protocol might be crucial. Even though DLS was not sensitive enough to detect any interaction with HSA (no significant difference in terms of Z-ave and PDI compared to the results obtained in the same dilution medium without HSA), AFM captured qualitative difference in the droplet topography (Figure 1), raising ides on nanoemulsion interfacial interaction with HSA and increased aggregation potential. Further on, SAXS confirmed the existence of a bilayer structure as indicated by a prominent correlation peak at around 1 nm-1, which corresponds to a bilayer thickness of around 6.2 nm. SAXS (Figure 2; probably corresponding to the lecithin formations at the interface). It may be assumed that the bilayer structure changes its structure when mixed with HSA. 
CONCLUSION
In this research, it has been demonstrated how important is to carefully select measurement conditions even for DLS -commonly used and the only standardized methods, in order to keep the measurements meaningful. Further on, not every method is capable of detecting some specific bio-nano interactions. Aiming to generate reliable datasets, condition sine qua non is to perform complementary techniques with increasing complexity. Further experimental segments should cover additional evaluation (e.g. analytical ultracentrifugation, thermal analysis, interfacial properties assessment, electron microscopy) that would shed light on bio-nano interactions important for in vivo fate of the nanosystems.
C3  - 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France
T1  - Sizing experiments and bio-nano interactions: method matters
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4571
ER  - 
@conference{
author = "Nikolić, Ines and Petrović, Marija and Krupnik, Leondard and Ranđelović, Danijela and Avaro, Jonathan and Neels, Antonia and Borchard, Gerrit and Jordan, Olivier and Đoković, Jelena and Savić, Snežana",
year = "2023",
abstract = "INTRODUCTION
Physicochemical properties of many active ingredients jeopardize their pharmacological activity. To overcome identified obstacles, nanosystems as carriers for delivery of actives have been recognized as promising tools. Increasing number of applications for registration of nanotechnology-enabled pharmaceuticals and many more currently in preclinical or clinical studies raised some questions not only in the field of research and development, but also for regulators. Given the complexity of nanosystems, some specific challenges have been encountered in their characterization, which have not been fully addressed despite respectable research tradition in this field.  Particle size and aggregation potential (especially in complex biological fluids) are some of the critical quality attributes of nanomedicines, being important in the context of physical stability of the colloidal system, and in terms of its safety profile and in vivo performance. Even though a bright future has been predicted for nanomedicines, some of the posted expectations have not been fully met so far. This might be reflected, at least at some points, in the certain methodological issues that commonly result in in vitro to in vivo translational gaps. This aspect underlines the importance of quality and safety assessment of nanomedicines which has also been recognized by globally leading research and regulatory bodies [1,2]. Therefore, the aim of the presented research was to perform a thorough analysis of the selected nanosystem (nanoemulsion) focusing on size estimation and particle-protein interaction applying several techniques, highlighting important factors for a reliable analysis.
METHODLOGY
Materials
As a model nanosystem, previously developed nanoemulsion was used, containing medium-chain triglycerides (Mygliol 812, Fagron) as the oil phase, combination of polysorbate 80 (Acros Organics) and soybean lecithin (Lipoid S-75, Lipoid) as stabilizes, and highly purified water as the water phase. For protein interaction assessment, human serum albumin was used (HSA, Sigma Aldrich).
Methods
Nanoemulsion preparation
Nanoemulsion was prepared via spontaneous emulsification, by dropwise addition of the mixture of the oil and stabilizers to the water phase under constant stirring. For nanoparticle-protein interaction assesment, nanoemulsion was incubated (1h, 37 °C) with HSA in the final concentration of 2.5 mg/ml. 
Sizing experiments – dynamic light scattering
Size and size distribution (per se and in biorelevant environment) were evaluated applying batch mode dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments, UK), following the NCL guidance [3]. Intensity-based average hydrodynamic diameter (Z-ave) and polydispersity index (PDI) were analysed in line with relevant parameters of the method. 
Atomic force microscopy (AFM)
Additional sizing analysis and morphological evaluation of the sample were performed applying AFM as a high-resolution technique. AFM analysis of the samples was performed by NTEGRA Prima atomic force microscope (NT-MDT, Moscow, Russia). Intermittent-contact AFM mode was applied using NT-MDT NSGO1 silicon, N-type, antimony doped cantilevers with Au reflective coating. Sample dilution corresponded to the optimal one selected for DLS, and 10 μl of the dilution was placed to the high-quality silica discs (Highest Grade V1 Mica Discs, Ted Pella Inc.) and dried in vacuum. Experiments were performed in the air, in contactless mode. Topographic images and “signal-error” images were collected, AFM images were created and analyzed with the software Image Analysis 2.2.0 (NT-MDT) and Gwyddion 2.60 (Free and Open Source software, Department of Nanometrology, Czech Metrology Institute).
Small angle X-ray scattering (SAXS)
SAXS experiments were performed with the general idea to analyze the structure of the dispersed nanodroplets more profoundly, and especially interactions in biorelevant surrounding (in contact with HSA). A laboratory X-ray setup was applied (Bruker Nanostar, Bruker AXS GmbH, Karlsruhe, Germany). Here, the Kα-line of a X-ray Cu source with a wavelength of 1.541 Å was used and further monochromated by a X-ray mirror. The beam was collimated to a beam diameter of approximately 0.4 mm using three pinholes. The sample-detector distance was set to 107 cm, which lead to a q-range of 0.07 ≤ q ≤ 2.3 nm-1. Calibration of the scattering vector q and estimation of the instrumental resolution of Δq = 0.25 nm-1 was done by measuring the first diffraction peak of a silver behenate sample. The scattered intensity was measured with an avalanche-based detector (VÅNTEC-2000, Bruker AXS). The transmitted part of the beam was determined using a home-made semi-transparent beam stop. The scattered intensity was extracted, radially averaged and integrated over all q-values using the Bruker software DIF-FRAC.EVA (Bruker AXS, version 4.1). The 1D data was transmission corrected and then background subtracted from the scattering of the solvent and the capillary using Matlab 2022.
RESULTS AND DISCUSSION
When applying DLS, as a preliminary technique, primary attention was put on the selection of optimal dilution level for the measurement, analyzing attenuation factor, count rate and intercept of the correlation function in different dilution ratios and with different dilution media (water, PBS 7.4 and 10 mM NaCl), and dilution 1:100 (v/v) was marked as the optimal one. However, significant differences in obtained nanodroplet size was observed depending on the type of medium. When water was used as a dilution medium, significantly higher Z-ave values were obtained (83.71±0.86 nm) compared to the situations where PBS 7.4 (73.50±0.75nm) or 10 mM NaCl (76.59±0.50nm) were used as dilution medium, indicating how sample preparation protocol might be crucial. Even though DLS was not sensitive enough to detect any interaction with HSA (no significant difference in terms of Z-ave and PDI compared to the results obtained in the same dilution medium without HSA), AFM captured qualitative difference in the droplet topography (Figure 1), raising ides on nanoemulsion interfacial interaction with HSA and increased aggregation potential. Further on, SAXS confirmed the existence of a bilayer structure as indicated by a prominent correlation peak at around 1 nm-1, which corresponds to a bilayer thickness of around 6.2 nm. SAXS (Figure 2; probably corresponding to the lecithin formations at the interface). It may be assumed that the bilayer structure changes its structure when mixed with HSA. 
CONCLUSION
In this research, it has been demonstrated how important is to carefully select measurement conditions even for DLS -commonly used and the only standardized methods, in order to keep the measurements meaningful. Further on, not every method is capable of detecting some specific bio-nano interactions. Aiming to generate reliable datasets, condition sine qua non is to perform complementary techniques with increasing complexity. Further experimental segments should cover additional evaluation (e.g. analytical ultracentrifugation, thermal analysis, interfacial properties assessment, electron microscopy) that would shed light on bio-nano interactions important for in vivo fate of the nanosystems.",
journal = "4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France",
title = "Sizing experiments and bio-nano interactions: method matters",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4571"
}
Nikolić, I., Petrović, M., Krupnik, L., Ranđelović, D., Avaro, J., Neels, A., Borchard, G., Jordan, O., Đoković, J.,& Savić, S.. (2023). Sizing experiments and bio-nano interactions: method matters. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France.
https://hdl.handle.net/21.15107/rcub_farfar_4571
Nikolić I, Petrović M, Krupnik L, Ranđelović D, Avaro J, Neels A, Borchard G, Jordan O, Đoković J, Savić S. Sizing experiments and bio-nano interactions: method matters. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4571 .
Nikolić, Ines, Petrović, Marija, Krupnik, Leondard, Ranđelović, Danijela, Avaro, Jonathan, Neels, Antonia, Borchard, Gerrit, Jordan, Olivier, Đoković, Jelena, Savić, Snežana, "Sizing experiments and bio-nano interactions: method matters" in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4571 .